Detecting lung cancer at early stages using a revolutionary microRNA platform technology.
Winner of 2022 MedTech Innovator Best Video Award
Benefits of our blood-based test for early lung cancer detection
There is currently no blood test or biological marker of lung cancer in clinical use. The development of a blood test that could improve screening selection or early detection especially in those not eligible for screening could have a transformational clinical impact.
The gold standard for lung cancer screening is Low Dose Computed Tomography (LDCT). According to the New England Journal of Medicine, the false positive rate of LDCT scan can be as high as 96%.
Our test can significantly reduce the false positive rate. This reduces the need of unnecessary scans and lung biopsy which is invasive and costly.
With our highly accurate test, healthcare costs can be greatly reduced.
Biopsy is invasive and may result in additional cost due to complications such collapsing of lungs or infection. The average cost of false positives is US$3,784 for lung biopsy and US$37,745 for complications per patient in the US.